COMPANY OVERVIEW

ViiV Healthcare is a global specialist HIV company established in November 2009 by GlaxoSmithKline (LSE: GSK) and Pfizer (NYSE: PFE) dedicated to delivering advances in treatment and care for people living with HIV and for people who are at risk of becoming infected with HIV. Shionogi joined as a shareholder in October 2012. The company’s aim is to take a deeper and broader interest in HIV/AIDS than any company has done before and take a new approach to deliver effective and innovative medicines for HIV treatment and prevention, as well as support communities affected by HIV.

---

LOCATION

Brentford, Middlesex, UK

---

THERAPEUTIC AREAS

---

WEBSITE

https://www.viivhealthcare.com/en-gb/

---

CAREER WEBSITE

https://www.viivhealthcare.com/en-gb/careers/

---

SOCIAL MEDIA

---

INVESTORS

---

---

PRESS RELEASES

Feb 23, 2023

ViiV Healthcare Announces Positive Data Demonstrating Long-acting Injectable Cabenuva (cabotegravir, rilpivirine) is as Effective as Daily Oral Biktarvy (BIC/FTC/TAF) for the Treatment of HIV-1

Feb 14, 2023

ViiV Healthcare to present first head-to-head data for long-acting HIV treatment Cabenuva against daily oral Biktarvy at CROI 2023

Nov 30, 2022

ViiV Healthcare Unveils a New Global Study Revealing Three Quarters of People Believe There Are Still Negative Perceptions When It Comes to People Living With HIV

Oct 25, 2022

ViiV Healthcare presents positive proof-of-concept findings for N6LS, an investigational, broadly neutralising antibody (bNAb) offering a potential new approach for the treatment of HIV

Oct 24, 2022

ViiV Healthcare Presents Positive Data Showing Vocabria (cabotegravir) and Rekambys (rilpivirine) Can Be Successfully Implemented Across a Range of European Healthcare Settings

For More Press Releases

---